The Paradigm Shift from Traditional Scientific Platforms to Integrated Communications Plans

In the rapidly evolving biopharma landscape, the approach to scientific communications is undergoing a significant transformation. The shift from traditional scientific platforms to integrated communications plans (ICPs) is becoming increasingly crucial for ensuring cohesive and impactful messaging. This article delves into the components, implementation, and benefits of an ICP tailored for the biopharma industry, addressing the challenges of fragmented messaging and the need for a unified communication strategy...
Read More

Top Stories

The Paradigm Shift from Traditional Scientific

In the rapidly evolving biopharma landscape, the approach to...
Involve Medical Affairs in insight management, early phases of clinical trials, etc.

It’s Never Too Soon: How and When to

Engagement with Medical Affairs is critical at every...
Health Literacy Month

Celebrating Health Literacy Month 2024:

October is Health Literacy Month, a reminder of the...
Image for R Discovery by Cactus

An End-to-End Literature Search Solution for Medical Writers | Medical Literature Search

Cactus Life Sciences offers an easy-to-use AI-based literature search tool for medical writers in pharma...
Pexels Alexander Suhorucov

Plain Language Summary Development in Japan: Current State and Challenges

This page contains supplementary information to support a poster presented at the Virtual 17th Annual...
Publication planning training

Publication Planning Training for Regional Medical Affairs Team

How a global pharma company overcame challenges of integration with regional teams in terms of...
EU MDR Whitepaper

EU MDR: Increasing Expectations for Clinical Evidence

While the global medical devices industry is closely watching how the European Union (EU) Medical...
A fireside chat on how MedTech leaders are called to respond to EU-MDR

Fireside Chat Part 1: How MedTech Leaders Are Called to Respond to EU MDR

A fireside chat on how MedTech leaders are called to respond to EU-MDR...

Learn more ABOUT our company.